Authors
Latest:
Dr Kouzy on the Creation of a Centralized Resource to Inform AI Use in Radiation OncologyRamez Kouzy, MD, discusses efforts to improve knowledge of the use of AI in radiation oncology through the creation of an online repository.
Latest:
ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLCBenjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
Latest:
Multidisciplinary Approaches to GVHDMedical experts discuss multidisciplinary approaches to GVHD.
Latest:
Dr Hajj Chehade on Potential Risk Factors for irAE Development in mRCCRazane El Hajj Chehade, MD, discusses the association between different histologic subtypes in renal cell carcinoma and the risk of developing immune-related adverse effects.
Latest:
The New Era of Clinical Trial DesignJill Gilbert, MD, highlights a recent landmark decision by the FDA concerning trial design moving forward for cancer drugs.
Latest:
Dr Baretti on Entinostat Plus Nivolumab in Advanced PDACMarina Baretti, MD, on results from a phase 2 study of entinostat in combination with nivolumab for the treatment of advanced pancreatic ductal adenocarcinoma.
Latest:
Dr. Halfdanarson on the Evolving Role of Immunotherapy in CRCThorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.
Latest:
Dr Phillips on the Evolution of BTK Inhibitors in MCLTycel Phillips, MD, discusses the evolution of treatment with BTK inhibitors for patients with mantle cell lymphoma.
Latest:
Dr Kim on the Addition of NALIRIFOX to the Pancreatic Cancer Treatment ParadigmDae Won Kim, MD, discusses findings from the NAPOLI 3 trial that support the use of NALIRIFOX in patients with metastatic pancreatic cancer.
Latest:
Tumor Lysis Syndrome: Unmet Needs and Future Directions in CareClosing out their discussion on tumor lysis syndrome management, James Short, MD, and John Reagan, MD, highlight unmet needs and future evolutions in the treatment landscape.
Latest:
Dr Manning-Geist on Secondary Cytoreductive Surgery in Ovarian CancerBeryl Manning-Geist, MD, discusses findings from a study evaluating the effects of primary treatment modality on secondary cytoreduction outcomes in patients with high-grade ovarian cancer.
Latest:
Normalizing Motherhood in MedicineHematology/oncology programs can make it easier and more rewarding for would-be mothers to participate in fellowship.
Latest:
Dr Al-Ali on the Safety and Efficacy of BMS-986158 Plus Ruxolitinib or Fedratinib in MyelofibrosisHaifa Kathrin Al-Ali, MD, discusses the safety and efficacy findings from the dose-escalation portion of the phase 1/2 CA011-023 trial of BMS-986158 in combination with ruxolitinib or fedratinib in patients with intermediate- or high-risk myelofibrosis.
Latest:
Dr Tripathy on the Treatment of HER2+ Breast CancerDebu Tripathy, MD, discusses the current state of HER2-positive breast cancer treatment.
Latest:
Dr. Kaplan on Real-World Surgical Retreatment Rates in LUTS/BPHSteven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.
Latest:
Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Guidance and Future PlansIn this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
Latest:
An Overview of the Molecular Characterization of Lung LCNECPanelists discuss how the characterization and classification of lung large cell neuroendocrine carcinoma (LCNEC) has evolved over the past decade, highlighting the clinical heterogeneity of these tumors and how it is navigated in clinical practice.
Latest:
Dr Gillenwater on Phase 1 Data for ASP-1929 Plus Pembrolizumab in HNSCCAnn M. Gillenwater, MD, discusses safety and efficacy data from the phase 1b/2 ASP-1929-181 trial evaluating the antibody-dye conjugate ASP-1929 in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Latest:
Dr Reed on Genetic Differences Between Ewing Sarcoma and OsteosarcomaDamon R. Reed, MD, discusses the genetic differences that distinguish Ewing sarcoma from osteosarcoma, as well as unmet needs in patients with these diseases.
Latest:
Boosting ‘Natural Killer’ Cell Activity Could Improve Cancer TherapyNatural killer cells hold promise for treating cancer; Yale researchers have found a way to overcome their main limitation.
Latest:
Dr. Rintoul on the Importance of MRD Assessment in NSCLCRobert Rintoul, BSc, MB ChB, PhD, FRCP, discusses the importance of minimal residual disease assessment in patients with non–small cell lung cancer.
Latest:
Dr Pederson on Novel Therapies for the Management of Targetable mCRCKatrina S. Pedersen, MD, MS, discusses key updates in the therapeutic landscape for patients with molecularly targetable metastatic colorectal cancer.
Latest:
Inside the Clinic: Experts Explore Case Studies in DLBCLMaher Albitar, MD, and Andre H. Goy, MD, discuss case studies in diffuse large B-cell lymphoma.
Latest:
Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin LymphomaTransposon-engineered BAFF ligand–based CAR T cells induced responses with a tolerable safety profile among 3 patients with relapsed/refractory B-cell NHL.
Latest:
Dr Kamath on the Rationale for Investigating Early-Onset vs Average-Onset PDACSuneel Kamath, MD, discusses the rationale for conducting an investigation into the tumor microbiome differences between early- and average-onset PDAC.
Latest:
Dr Sanai on the Evaluation of BDTX-1535 in EGFR-Mutated High-Grade GlioblastomaNader Sanai, MD, discusses a phase 1 trial investigating BDTX-1535 in patients with recurrent, EGFR-mutated high-grade glioblastoma.
Latest:
Breaking New Ground in Biological Therapies for CancerThe financial performance of Florida Cancer Specialists & Research Institute for the first two months of 2024 surpassed the statewide practice’s budget.
Latest:
An Overview of Advanced Basal Cell Carcinoma (BCC) and Currently Available Treatment OptionsDr Hanna defines basal cell carcinoma (BCC), reviews current treatment options and explains the role of cemiplimab for the treatment of advanced BCC.
